







a**b****c**

Supplementary Figure 1 | β_2 AR data analysis. (a) Raw data of concentration response curves of β_2 AR for the five monitored pathways were determined with log(agonist) vs response -- Variable slope (four parameters) in Prism. Fitted values for the Hill slope were also used when fitting the β_2 AR variants and are given here. Data shown are representatives of at least 3 independent experiments performed in duplicate. Data analysis (b) for BRET-based assays and (c) ELISA-based assay. For details see Methods.






Supplementary Figure 3 | Correction for the variation in cell surface expression level. In order to correct for the difference in cell surface expression of the different β_2 AR variants, concentration response curves for WT β_2 AR using 5% to 150% of DNA-amount used for the variants were generated for each assay (Gs-activation, Gi activation, cAMP production, β arrestin recruitment and endocytosis) and cell surface expression measured (**Fig. 3a**). The signalling parameters (basal, maximal and ISO-induced activity, pEC_{50} and $\log T/K_A$) were then determined for each % of WT β_2 AR DNA for each assay and their correlation to expression level calculated (**Fig. 3b**).




Supplementary Figure 4 | Radial graphs of signaling signature for each mutant. (a) cluster 1, (b) cluster 2 and (c) cluster 3. Signaling signature for four V86-mutations with increasing EA score are highlighted by red squares. The low EA-score mutation (V86I) slightly increases basal G-protein activation and slightly reduces ISO-stimulated Gs-activation and β arrestin2-engagement. The medium low EA-score mutation (V86A) increases basal G-protein activity, as well as maximal and ISO-induced Gi activation. ISO-stimulated Gs-activation and β arrestin2-engagement are slightly reduced. The medium high EA-score mutation (V86Y) increases basal G-protein activation and Gi maximal activity. Additionally, a decrease in ISO-stimulated Gs-activation and no response to ISO in Gi activation, β arrestin2-engagement and endocytosis are observed. The high EA-score mutation (V86D) shows a similar phenotype to V86Y, but slightly more pronounced. Data is shown as normalized difference (mut-WT/mut+WT). WT is shown in red as reference and each receptor variant is shown in blue.









Supplementary Figure 5 | Predicted changes within 4.5 Å of each mutated position on the inactive conformation. (a) cluster 1, (b) cluster 2 and (c) cluster 3 are mapped on the inactive conformation (pdb: 2RH1).



Supplementary Figure 6 | Predicted changes within 4.5 Å of each mutated position on the active conformation. (a) cluster 1, (b) cluster 2 and (c) cluster 3 are mapped on the active conformation (pdb: 4LDE).



Supplementary Figure 7 | Transferability of mutations from β_2 AR to V2R. Concentration response curves for (a) Gs activation, (b) cAMP production and (c) Barrestin recruitment of $I^{6.40}$ position in β_2 AR and V2R. Mutants are shown in red and an equivalent concentration of WT receptor in blue. Data show that the mutation is transferable from the β_2 AR to the V2R with similar effects. I276V/L doesn't or slightly affect Gs activation, cAMP production and Barrestin recruitment whereas the I276Q variant affects Barrestin recruitment without affecting the two other pathways. Data shown are the average \pm s.e.m. of at least 3 independent experiments performed in duplicate.



Supplementary Figure 8 | BRET-based binding assay. (a) Principle of BRET-based binding assay. (b) Schematic representation of receptor constructs. The receptor was modified at the N-terminus as indicated. (c) ISO-induced cAMP-production is not changed in Nluc-β₂AR. (d) The K_d of the radioligand CpG12177 to Nluc-β₂AR is slightly increased. (e) Total and non-specific binding of (S)-Propranolol-green was determined by saturation experiments. (f) For several β₂AR ligands the pK_i can be determined in competition with 100nM (S)-Propranolol-green and fitting with “One-site - Fit Ki” for competition binding in Prism. All data shown are representatives of at least 2 independent experiments performed in duplicate.

Supplementary Table 1 | Evolutionary importance (ET), distance to the ligand and to the nearest water molecule and substituted amino acid with evolutionary action score (EA) for each mutational target.

	ET score	dist to ligand Å	dist to water Å	Mutation (EA-score)
A78 ^{2.49}	24	10.4	6.4	V (58) N (70) W (58)
V86 ^{2.57}	33	5.9	9.3	I (26) A (53) Y (73) D (90)
L124 ^{3.43}	7	12.7	5.5	M (55) S (97) G (99)
I127 ^{3.46}	7	17.7	7.4	V (59) N (94) G (99)
I278 ^{6.40}	18	15.7	2.9	V (41) L (49) S (89) Q (90)
K273 ^{6.35}	37	23.9	9.8	R (27) L (69) A (66)
R328 ^{7.55}	39	25.1	9.3	K (27) H (42) L (63) A (63)
R333 ^{8.51}	n. d.	30.7	10.2	L (n. d.) A (n. d.)
A271 ^{6.33}	31	25.7	6.0	T (54) W (78)

n. d., not determined; Ballesteros-Weinstein numbering⁴² is given in superscript

Supplementary Table 2 | Signaling parameters of Gs-activation of 28 β_2 AR variants.

	basal	max	ISO	pEC₅₀	logT/Ka
WT (13)	46 ± 2	104 ± 4	58 ± 4	7.2 ± 03	6.7 ± 0.2
A78V (6)	57 ± 2	100 ± 5	43 ± 4	6.4 ± 0.4	5.9 ± 0.4
A78N (5)	62 ± 2	93 ± 4	31 ± 4	6.9 ± 0.5	6.1 ± 0.5
A78W (5)	67 ± 2	89 ± 4	22 ± 4	7.2 ± 0.8	6.0 ± 0.7
V86I (6)	62 ± 3	102 ± 7	40 ± 7	6.3 ± 0.7	5.6 ± 0.3
V86A (6)	56 ± 2	93 ± 5	37 ± 5	6.3 ± 0.5	5.5 ± 0.4
V86Y (5)	63 ± 3	78 ± 7	15 ± 7	6.7 ± 2.0	4.9 ± 1.1
V86D (5)	57 ± 2	81 ± 5	24 ± 5	6.7 ± 0.9	5.3 ± 0.7
L124M (3)	70 ± 4	112 ± 4	42 ± 5	8.4 ± 0.6	8.4 ± 0.6
L124S (3)	61 ± 8	86 ± 3	25 ± 8	10.7 ± 1.4	8.6 ± 1.0
L124G (3)	38 ± 6	63 ± 3	25 ± 6	10.1 ± 1.2	7.6 ± 0.9
I127V (3)	61 ± 3	113 ± 3	51 ± 4	8.4 ± 0.3	8.4 ± 0.4
I127N (3)	58 ± 3	107 ± 4	49 ± 5	7.9 ± 0.4	7.5 ± 0.4
I127G (3)	55 ± 3	98 ± 4	44 ± 4	8.2 ± 0.5	7.6 ± 0.4
I278V (6)	61 ± 3	115 ± 7	55 ± 7	6.3 ± 0.5	6.4 ± 0.3
I278L (3)	40 ± 3	105 ± 4	65 ± 4	8.1 ± 0.3	7.6 ± 0.3
I278S (3)	72 ± 3	111 ± 3	39 ± 4	8.2 ± 0.5	8.0 ± 0.5
I278Q (3)	32 ± 4	71 ± 3	40 ± 4	9.1 ± 0.6	7.6 ± 0.5
K273R (3)	18 ± 4	86 ± 3	68 ± 4	9.1 ± 0.3	8.2 ± 0.3
K273L (3)	53 ± 4	116 ± 5	62 ± 6	8.2 ± 0.4	8.4 ± 0.3
K273A (3)	70 ± 4	124 ± 5	54 ± 5	8.0 ± 0.5	8.9 ± 0.5
R328K (3)	19 ± 3	85 ± 2	65 ± 3	9.2 ± 0.3	8.2 ± 0.3
R328H (6)	64 ± 2	104 ± 7	40 ± 6	6.3 ± 0.7	5.6 ± 0.3
R328L (3)	15 ± 3	82 ± 3	67 ± 3	8.2 ± 0.2	7.4 ± 0.3
R328A (3)	22 ± 3	80 ± 3	58 ± 4	8.3 ± 0.3	7.3 ± 0.3
R333L (3)	63 ± 3	119 ± 4	56 ± 5	8.2 ± 0.4	8.6 ± 0.4
R333A (3)	70 ± 3	120 ± 4	49 ± 4	8.4 ± 0.4	9.0 ± 0.5
A271T (6)	62 ± 3	116 ± 9	54 ± 9	6.0 ± 0.6	6.2 ± 0.3
A271W (3)	60 ± 3	101 ± 5	40 ± 5	6.9 ± 0.6	5.9 ± 0.4

Basal, maximal (max) and ISO-induced (ISO) activity are given as % of WT maximal activity. Potency (pEC₅₀) is expressed as -log EC₅₀ M. Signaling efficiency (logT/Ka) was calculated as described in Methods. All data are given as average ± s.e.m. of at least 3 independent experiments performed in duplicate. n for each receptor variant is given in brackets. Note: data in this table are not corrected for expression levels.

Supplementary Table 3 | Signaling parameters of Gi-activation of 28 β_2 AR variants.

	basal	max	ISO	pEC ₅₀	logT/Ka
WT (22)	28 ± 3	96 ± 5	68 ± 5	7.3 ± 0.2	6.7 ± 0.2
A78V (4)	67 ± 3	67 ± 3	0	n. d.	n. d.
A78N (3)	101 ± 6	142 ± 14	41 ± 14	6.6 ± 0.9	4.1 ± 0.6
A78W (4)	85 ± 4	85 ± 4	0	n. d.	n. d.
V86I (7)	66 ± 13	115 ± 13	49 ± 17	8.2 ± 0.9	7.5 ± 0.4
V86A (3)	76 ± 5	148 ± 53	72 ± 52	4.5 ± 1.1	3.9 ± 0.4
V86Y (3)	79 ± 4	79 ± 4	0	n. d.	n. d.
V86D (3)	147 ± 7	147 ± 7	0	9.9 ± 2.5	n. d.
L124M (4)	76 ± 8	110 ± 4	34 ± 8	8.5 ± 0.6	7.7 ± 1.1
L124S (3)	39 ± 4	39 ± 4	0	n. d.	n. d.
L124G (3)	54 ± 3	54 ± 3	0	n. d.	n. d.
I127V (3)	81 ± 6	105 ± 5	24 ± 7	7.7 ± 0.7	6.6 ± 1.5
I127N (3)	120 ± 5	120 ± 5	0	n. d.	n. d.
I127G (4)	74 ± 3	74 ± 3	0	n. d.	n. d.
I278V (5)	95 ± 9	196 ± 17	100 ± 18	6.6 ± 0.5	6.6 ± 0.3
I278L (4)	52 ± 3	72 ± 6	19 ± 7	5.9 ± 0.9	4.7 ± 1.7
I278S (4)	75 ± 3	75 ± 3	0	n. d.	n. d.
I278Q (3)	25 ± 3	25 ± 3	0	n. d.	n. d.
K273R (4)	60 ± 6	92 ± 7	31 ± 8	6.9 ± 0.6	5.8 ± 0.9
K273L (4)	28 ± 9	57 ± 5	29 ± 10	8.7 ± 0.9	7.6 ± 1.3
K273A (4)	54 ± 8	88 ± 6	34 ± 9	8.0 ± 0.6	7.0 ± 0.9
R328K (4)	82 ± 5	105 ± 8	24 ± 9	6.3 ± 0.9	5.3 ± 1.3
R328H (5)	47 ± 6	121 ± 10	74 ± 11	6.8 ± 0.4	6.3 ± 0.4
R328L (4)	107 ± 3	107 ± 3	0	n. d.	n. d.
R328A (5)	94 ± 4	94 ± 4	0	n. d.	n. d.
R333L (4)	64 ± 5	64 ± 5	0	n. d.	n. d.
R333A (4)	81 ± 7	108 ± 6	28 ± 9	7.6 ± 0.8	6.6 ± 1.1
A271T (5)	61 ± 9	141 ± 15	80 ± 16	6.9 ± 0.5	6.6 ± 0.4
A271W (4)	108 ± 5	108 ± 5	0	n. d.	n. d.

Basal, maximal (max) and ISO-induced (ISO) activity are given as % of WT maximal activity. Potency (pEC₅₀) is expressed as -log EC₅₀ M. Signaling efficiency (logT/Ka) was calculated as described in Methods. All data is given as average ± s.e.m. of at least 3 independent experiments performed in duplicate. n for each receptor variant is given in brackets. Note: data in this table is not corrected for expression levels. n. d., not determined

Supplementary Table 4 | Signaling parameters of cAMP-production of 28 β_2 AR variants.

	basal	max	ISO	pEC ₅₀	logT/Ka
WT (23)	58 ± 2	99 ± 1	41 ± 2	8.8 ± 0.1	8.5 ± 0.1
A78V (5)	60 ± 4	105±4	45 ± 6	7.8 ± 0.3	7.5 ± 0.2
A78N (4)	34 ± 3	85 ± 4	51 ± 4	7.3 ± 0.3	6.9 ± 0.3
A78W (5)	76 ± 3	93 ± 4	17 ± 5	7.5 ± 0.8	7.0 ± 0.7
V86I (5)	80 ± 4	100 ± 3	20 ± 4	8.3 ± 0.6	7.9 ± 0.6
V86A (5)	59 ± 4	90 ± 4	31 ± 5	7.7 ± 0.4	7.3 ± 0.4
V86Y (5)	18 ± 3	76 ± 4	57 ± 5	6.7 ± 0.2	6.3 ± 0.2
V86D (5)	29 ± 3	78 ± 5	49 ± 6	6.7 ± 0.3	6.3 ± 0.2
L124M (6)	68 ± 5	102 ± 2	34 ± 5	9.8 ± 0.4	9.6 ± 0.4
L124S (4)	40 ± 7	61 ± 3	21 ± 7	10.4 ± 0.9	9.5 ± 0.9
L124G (4)	19 ± 5	36 ± 2	17 ± 5	10.4 ± 1.2	9.3 ± 1.2
I127V (6)	45 ± 4	110 ± 3	65 ± 5	8.8 ± 0.2	8.7 ± 0.2
I127N (4)	23 ± 5	79 ± 5	57 ± 6	7.9 ± 0.3	7.5 ± 0.2
I127G (7)	22 ± 3	76 ± 2	54 ± 3	8.0 ± 0.2	7.6 ± 0.2
I278V (7)	63 ± 7	105 ± 4	43 ± 7	8.7 ± 0.3	8.4 ± 0.2
I278L (6)	23 ± 3	90 ± 3	68 ± 4	8.3 ± 0.2	8.1 ± 0.2
I278S (6)	56 ± 5	107 ± 3	51 ± 5	9.2 ± 0.3	9.0 ± 0.2
I278Q (4)	35 ± 5	70 ± 3	35 ± 6	9.1 ± 0.5	8.5 ± 0.5
K273R (6)	39 ± 5	87 ± 2	48 ± 5	9.3 ± 0.3	8.9 ± 0.3
K273L (9)	48 ± 4	96 ± 2	47 ± 5	9.2 ± 0.3	8.9 ± 0.2
K273A (7)	53 ± 6	98 ± 3	45 ± 7	9.2 ± 0.3	9.0 ± 0.2
R328K (6)	32 ± 4	94 ± 3	63 ± 5	8.6 ± 0.2	8.4 ± 0.2
R328H (5)	91 ± 5	120 ± 4	29 ± 6	7.9 ± 0.5	8.3 ± 0.6
R328L (3)	12 ± 3	70 ± 3	58 ± 3	7.9 ± 0.3	7.5 ± 0.2
R328A (4)	10 ± 2	73 ± 2	64 ± 3	8.0 ± 0.3	7.6 ± 0.3
R333L (9)	43 ± 4	97 ± 3	54 ± 4	8.9 ± 0.2	8.7 ± 0.2
R333A (6)	60 ± 5	105 ± 3	45 ± 5	9.0 ± 0.2	8.8±0.2
A271T (7)	81 ± 5	117 ± 4	36 ± 6	8.5 ± 0.3	8.7±0.3
A271W (8)	15 ± 3	76 ± 3	61 ± 4	7.6 ± 0.2	7.2±0.1

Basal, maximal (max) and ISO-induced (ISO) activity are given as % of WT maximal activity. Potency (pEC₅₀) is expressed as -log EC₅₀ M. Signaling efficiency (logT/Ka) was calculated as described in Methods. All data is given as average ±s.e.m. of at least 3 independent experiments performed in duplicate. n for each receptor variant is given in brackets. Note: data in this table is not corrected for expression levels.

Supplementary Table 5 | Signaling parameters of βarrestin2-engagement of 28 β₂AR variants.

	max	ISO	pEC ₅₀	logT/Ka
WT (27)	98 ± 2	69 ± 3	7.0 ± 0.1	7.0 ± 0.1
A78V (6)	15 ± 3	0	n. d.	n. d.
A78N (6)	31 ± 4	0	n. d.	n. d.
A78W (4)	49 ± 2	0	n. d.	n. d.
V86I (5)	110 ± 5	44 ± 6	6.9 ± 0.3	6.5 ± 0.2
V86A (5)	52 ± 3	20 ± 4	6.6 ± 0.4	6.2 ± 0.6
V86Y (4)	38 ± 3	0	n. d.	n. d.
V86D (9)	51 ± 2	0	n. d.	n. d.
L124M (4)	84 ± 4	43 ± 7	8.2 ± 0.3	8.1 ± 0.5
L124S (4)	28 ± 3	0	n. d.	n. d.
L124G (4)	39 ± 2	0	n. d.	n. d.
I127V (4)	73 ± 5	42 ± 6	7.1 ± 0.3	6.9 ± 0.4
I127N (4)	15 ± 2	0	n. d.	n. d.
I127G (4)	7 ± 1	0	n. d.	n. d.
I278V (6)	105 ± 5	96 ± 6	6.6 ± 0.1	6.6 ± 0.1
I278L (4)	59 ± 5	49 ± 6	6.3 ± 0.2	6.1 ± 0.4
I278S (5)	34 ± 3	0	n. d.	n. d.
I278Q (4)	44 ± 3	0	n. d.	n. d.
K273R (4)	87 ± 5	35 ± 6	7.3 ± 0.4	7.1 ± 0.6
K273L (4)	82 ± 4	70 ± 6	7.4 ± 0.2	7.3 ± 0.2
K273A (8)	53 ± 4	38 ± 6	7.8 ± 0.3	7.6 ± 0.4
R328K (4)	95 ± 5	38 ± 6	6.5 ± 0.4	6.4 ± 0.5
R328H (9)	87 ± 6	65 ± 7	6.5 ± 0.2	6.4 ± 0.1
R328L (4)	71 ± 4	37 ± 4	6.4 ± 0.3	6.2 ± 0.6
R328A (4)	60 ± 4	20 ± 4	6.1 ± 0.4	5.7 ± 0.9
R333L (8)	77 ± 5	32 ± 7	7.1 ± 0.4	6.9 ± 0.6
R333A (4)	89 ± 3	45 ± 5	7.4 ± 0.2	7.3 ± 0.3
A271T (6)	128 ± 6	85 ± 7	6.9 ± 0.2	6.9 ± 0.1
A271W (4)	14 ± 3	15 ± 3	6.1 ± 0.4	5.4 ± 1.2

Basal, maximal (max) and ISO-induced (ISO) activity are given as % of WT maximal activity. Potency (pEC₅₀) is expressed as -log EC₅₀ M. Signaling efficiency (logT/Ka) was calculated as described in Methods. All data is given as average ± s.e.m. of at least 3 independent experiments performed in duplicate. n for each receptor variant is given in brackets. Note: data in this table is not corrected for expression levels. n. d., not determined

Supplementary Table 6 | Signaling parameters of endocytosis of 28 β_2 AR variants.

	max	ISO	pEC₅₀	logT/Ka
WT (19)	96 ± 3	96 ± 3	7.5 ± 0.1	7.5 ± 0.1
A78V (7)	41 ± 4	41 ± 4	6.6 ± 0.2	6.5 ± 0.2
A78N (4)	13 ± 2	13 ± 2	6.3 ± 0.3	n. d.
A78W (5)	18 ± 3	18 ± 3	7.8 ± 0.3	n. d.
V86I (4)	92 ± 3	92 ± 3	7.3 ± 0.1	7.3 ± 0.1
V86A (7)	54 ± 3	54 ± 3	7.1 ± 0.1	7.0 ± 0.2
V86Y (8)	-5 ± 1	0	n. d.	n. d.
V86D (5)	15 ± 3	15 ± 3	6.3 ± 0.3	n. d.
L124M (7)	117 ± 5	117 ± 5	8.6 ± 0.1	8.6 ± 0.1
L124S (6)	12 ± 2	12 ± 2	9.2 ± 0.5	n. d.
L124G (6)	6 ± 1	0	n. d.	n. d.
I127V (6)	84 ± 5	84 ± 5	7.6 ± 0.1	7.6 ± 0.1
I127N (6)	17 ± 2	17 ± 2	6.6 ± 0.3	n. d.
I127G (6)	12 ± 2	12 ± 2	7.5 ± 0.5	n. d.
I278V (8)	137 ± 8	137 ± 8	6.8 ± 0.1	6.8 ± 0.1
I278L (6)	59 ± 5	59 ± 5	7.0 ± 0.2	6.9 ± 0.2
I278S (8)	28 ± 2	28 ± 2	8.2 ± 0.2	7.9 ± 0.4
I278Q (6)	10 ± 2	10 ± 2	8.0 ± 0.5	n. d.
K273R (5)	105 ± 6	105 ± 6	8.1 ± 0.1	8.2 ± 0.1
K273L (4)	19 ± 4	19 ± 4	8.0 ± 0.5	n. d.
K273A (3)	134 ± 7	134 ± 7	8.2 ± 0.1	8.2 ± 0.1
R328K (5)	120 ± 8	120 ± 8	7.3 ± 0.2	7.2 ± 0.1
R328H (5)	92 ± 6	92 ± 6	6.7 ± 0.1	6.7 ± 0.1
R328L (5)	107 ± 6	107 ± 6	7.0 ± 0.1	7.0 ± 0.1
R328A (8)	47 ± 5	47 ± 5	5.8 ± 0.2	5.7 ± 0.3
R333L (6)	67 ± 4	67 ± 4	7.5 ± 0.1	7.5 ± 0.2
R333A (6)	109 ± 7	109 ± 7	8.3 ± 0.2	8.4 ± 0.1
A271T (4)	126 ± 5	126 ± 5	7.3 ± 0.1	7.3 ± 0.1
A271W (5)	-2 ± 4	0	n. d.	n. d.

Basal, maximal (max) and ISO-induced (ISO) activity are given as % of WT maximal activity. Potency (pEC₅₀) is expressed as -log EC₅₀ M. Signaling efficiency (logT/Ka) was calculated as described in Methods. All data is given as average ± s.e.m. of at least 3 independent experiments performed in duplicate. n for each receptor variant is given in brackets. Note: data in this table is not corrected for expression levels. n. d., not determined

Supplementary Table 8 | Ligand binding parameters determined by BRET-based binding.

pK _i (ISO)	
WT (5)	6.2 ± 0.3
A78V (4)	5.8 ± 0.1
A78N (5)	5.9 ± 0.5
A78W (5)	6.6 ± 0.5
V86I (4)	6.1 ± 0.2
V86A	n. d.
V86Y	n. d.
V86D	n. d.
L124M (4)	6.3 ± 0.3
L124S (5)	8.1 ± 0.6
L124G (5)	n. d.
I127V (4)	6.5 ± 0.2
I127N (5)	7.7 ± 0.4
I127G (5)	6.2 ± 0.7
I278V (4)	5.6 ± 0.2
I278L (4)	7.3 ± 0.1
I278S (4)	7.3 ± 0.1
I278Q (4)	8.3 ± 0.5
K273R (4)	6.5 ± 0.2
K273L (4)	6.5 ± 0.1
K273A (4)	6.0 ± 0.3
R328K (4)	5.9 ± 0.1
R328H (4)	5.9 ± 0.1
R328L (4)	5.9 ± 0.2
R328A (4)	6.2 ± 0.3
R333L (5)	6.4 ± 0.3
R333A (4)	6.3 ± 0.1
A271T (5)	5.8 ± 0.3
A271W (4)	5.8 ± 0.1

The K_D of the fluorescent ligand (S)-Propranolol-green was determined by saturation binding for each variant of the β₂AR and was followed by the determination of pK_i for ISO by competition binding studies. Data is given as average ± s.e.m. of at least 3 independent experiments performed in duplicate. n for each receptor variant is given in brackets. n. d., not determined